Back
Entrada Therapeutics 10K Form
Sell
41
TRDA
Entrada Therapeutics
Last Price:
13.68
Seasonality Move:
13.84%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TRDA News And Ratings
See the #1 stock for the next 7 days that we like better than TRDA
TRDA Financial Statistics
Sales & Book Value
| Annual Sales: | $129.01M |
|---|---|
| Cash Flow: | $38.79M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $11.57 |
| Price / Book: | 1.23 |
Profitability
| EPS (TTM): | 2.96000 |
|---|---|
| Net Income (TTM): | $104.44M |
| Gross Margin: | -- |
| Return on Equity: | 37.43% |
| Return on Assets: | 20.55% |
Entrada Therapeutics Earnings Forecast
Key Entrada Therapeutics Financial Ratios
- The Research & Development expenses have been 77.42% of Revenue.
- The Net Earning history of TRDA is -5.18% of Total Revenues.
- Per Share Earnings over the last 5 years have been positive in 2 years.
Entrada Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | TRDA |
| Website: | entradatx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 5.7 |
| Quick Ratio: | 5.56 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
TRDA Technical Analysis vs Fundamental Analysis
Sell
41
Entrada Therapeutics (TRDA)
is a Sell
Is Entrada Therapeutics a Buy or a Sell?
-
Entrada Therapeutics stock is rated a Sell
The current Entrada Therapeutics [TRDA] share price is $14.16. The Score for TRDA is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.